沙利度胺改善恶性肿瘤患者围化疗期恶心、呕吐的临床研究  

Clinical study of treatment of peri-chemotherapy nausea and vomiting of cancer patients using thalidomide

作　　者：韩正祥[1] 孙旋[1] 徐杰[1] 李艳[1] 杜秀平[1] 

机构地区：[1]徐州医学院附属医院肿瘤科,221002

出　　处：《肿瘤研究与临床》2014年第10期667-669,共3页Cancer Research and Clinic

基　　金：江苏省卫生厅医学科技发展基金会临床肿瘤学科研课题（P200942）;徐州医学院课题（08KJ53）

摘　　要：目的 探讨沙利度胺治疗恶性肿瘤患者围化疗期恶心、呕吐的临床疗效及不良反应.方法 70例患者随机分为治疗组（38例）和对照组（32例）.治疗组于化疗前1d晚睡前开始顿服沙利度胺,起始剂量第1周100 mg/d,如能耐受不良反应,每晚增加50 mg,直至按剂量200 mg/d维持,如不能耐受加量者,则维持原剂量,服用至围化疗期结束;同时化疗前30 min静脉注射托烷司琼2 mg.对照组于化疗前30min静脉注射托烷司琼2mg,评价两组的止吐效果及不良反应.结果 治疗组与对照组的呕吐控制有效率分别为89.5％（34/38）、68.8％（22/32）,差异有统计学意义（P＜0.05）;两组的不良反应类似,差异无统计学意义（P＞0.05）.结论 沙利度胺联合托烷司琼可有效改善恶性肿瘤患者围化疗期的呕吐,不良反应可耐受,进一步提高了沙利度胺临床抗肿瘤治疗的适应证.Objective To explore the therapeutic effects and adverse reactions of thalidomide in the treatment of peri-chemotherapy nausea and vomiting of cancer patients.Methods Total of 70 patients were randomly divided into two groups：the treatment group （38 cases） and the control group （32 cases）.The treatment group was treated with thalidomide （oral administration at a dose of 100 mg per night,then dose can be added by 50 mg until the top dose of 200 mg per day）.The original will be maintained if they cannot be tolerate of extensive dose.The treatment group was also injected 2mg tropisetron in 30 minutes before chemotherapy.The control group was only injected same dose tropisetron.All cases were examined antiemetic effects and evaluated adverse reactions.Results Nausea and vomiting control rates were 89.5 % （34/38） and 68.8 % （22/32） respectively in the treatment group and control group respectively with significant difference.The adverse reactions were similar between the two groups.Conclusion Thalidomide joint tropisetron can effectively control the peri-chemotherapy nausea and vomiting,and the adverse reactions can be acceptable.It could improve further indications of the drug.

关 键 词：肿瘤 沙利度胺 围化疗期 恶心 呕吐 

分 类 号：R730.53[医药卫生—肿瘤]